Do statins pose a risk on a range of illnesses / clinical outcomes?
- Hippisley-Cox, J., Coupland, C., 2010. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 340, c2197–c2197.
- 2,004,692 patients aged 30-84 years
- Statistical models were used to estimate the effects of statin type, dose, and duration of use.
- The clinical outcomes being measured were the first recorded occurrence of cardiovascular disease, moderate or serious myopathic events, moderate or serious liver dysfunction, acute renal failure, venous thromboembolism, Parkinson’s disease, dementia, rheumatoid arthritis, cataract, osteoporotic fracture, gastric cancer, oesophageal cancer, colon cancer, lung cancer, melanoma, renal cancer, breast cancer, or prostate cancer.
- Individual statins were not significantly associated with a risk of Parkinson’s disease, rheumatoid arthritis, venous thromboembolism, dementia, osteoporotic fracture, and several common cancers
- The risk of oesophageal cancer was reduced but for liver dysfunction, acute renal failure, myopathy, and cataract it was increased
- Adverse effects were similar across the statin types for each outcome except liver dysfunction where fluvastatin was associated with the highest risks.
- Yes (with confidence) for acute renal failure, myopathy, cataract and liver dysfunction (with the use of fluvastatin) it was increased
- No (with confidence) for Parkinson’s disease, rheumatoid arthritis, venous thromboembolism, dementia, osteoporotic fracture, and several common cancers
Meta-analyses suggest that statins reduce the risk of cardiovascular disease, particularly in high risk patients. However, the unintended effects of statins in primary care populations is lacking.